Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Pharmacological profile of SR-141716A, a selective CB1 antagonist, further characterized

Dec. 29, 1999

Brain cocaine receptor ligands from RTI with favorable properties for pharmaceutical, imaging use

Dec. 28, 1999

New agent for treating cocaine dependency in development at RBI

Dec. 22, 1999

Preclinical studies validate Nabi's novel approach to treating and preventing nicotine addiction

Dec. 20, 1999

Novartis reports setbacks and advances in the development of new chelating agents

Dec. 8, 1999

Glaxo Wellcome's Zyban approved in The Netherlands for smoking cessation

Dec. 3, 1999

Neuronal nicotinic acetylcholine receptor ligands in early development at Pfizer

Nov. 30, 1999

Pfizer discloses modulators of cholinergic function for smoking cessation, etc.

Nov. 29, 1999

Development of potential new antiaddictive agent supported by NIDA

Oct. 22, 1999

FDA accepts DigiTAb filing for review

Oct. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...